Literature DB >> 21936030

Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study.

Marte L Hoivik1, Bjorn Moum, Inger C Solberg, Milada Cvancarova, Ole Hoie, Morten H Vatn, Tomm Bernklev.   

Abstract

BACKGROUND: Ulcerative colitis (UC) negatively affects health-related quality of life (HRQoL), but population-based and long-term data on this topic are scarce. Our aim was to determine the HRQoL in UC patients after a 10-year disease duration.
METHODS: UC patients from a population-based inception cohort met at a prescheduled 10-year follow-up visit. In addition to a clinical examination, interview, and blood samples, the patients completed the Short Form 36 (SF-36) and the Norwegian Inflammatory Bowel Disease Questionnaire (N-IBDQ). The SF-36 scores were compared to scores from a general population sample using one-sample t-tests. Standardized scores were calculated and interpreted according to Cohen's effect size index. The associations between relevant clinical and demographic factors and HRQoL were examined through linear regression analyses.
RESULTS: A total of 196 patients completed the HRQoL questionnaires (response rate: 80%), of whom 54% were women; the mean age of all patients was 48 years (range: 22-86). The SF-36 scores were comparable to those of the general population except for lower scores in the General Health dimension. The SF-36 scores were significantly lower in the presence of current symptoms, in patients who had used corticosteroids, and in patients who reported not working. Overall N-IBDQ scores were equivalent to scores of patients in remission. Female gender, work status (not working), current symptoms, and smoking were associated with significantly lower N-IBDQ scores.
CONCLUSIONS: SF-36 scores were not reduced compared to the general population sample. The presence of current symptoms, the use of corticosteroids, work status (not working), female gender, and smoking had a negative impact on HRQoL.
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21936030     DOI: 10.1002/ibd.21863

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  31 in total

1.  Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine.

Authors:  Sufeng Zhang; Won Joon Cho; Amy T Jin; Lie Yun Kok; Yunhua Shi; David E Heller; Young-Ah Lucy Lee; Yixuan Zhou; Xi Xie; Joshua R Korzenik; Jochen K Lennerz; Giovanni Traverso
Journal:  Adv Healthc Mater       Date:  2020-06-29       Impact factor: 9.933

2.  Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort.

Authors:  Lea K Christiansen; Bobby Lo; Flemming Bendtsen; Ida Vind; Marianne K Vester-Andersen; Johan Burisch
Journal:  United European Gastroenterol J       Date:  2019-05-17       Impact factor: 4.623

Review 3.  Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review.

Authors:  Aaron Yarlas; Martha Bayliss; Joseph C Cappelleri; Stephen Maher; Andrew G Bushmakin; Lea Ann Chen; Alireza Manuchehri; Paul Healey
Journal:  Qual Life Res       Date:  2017-08-28       Impact factor: 4.147

Review 4.  Mesalamine in the treatment and maintenance of remission of ulcerative colitis.

Authors:  Maggie Ham; Alan C Moss
Journal:  Expert Rev Clin Pharmacol       Date:  2012-03       Impact factor: 5.045

5.  Protease-activated receptor-2 activation enhances epithelial wound healing via epidermal growth factor receptor.

Authors:  Mahesha Bandara; Wallace K MacNaughton
Journal:  Tissue Barriers       Date:  2021-09-11

Review 6.  Sex Differences in the Gut-Brain Axis: Implications for Mental Health.

Authors:  Calliope Holingue; Alexa Curhan Budavari; Katrina M Rodriguez; Corina R Zisman; Grace Windheim; M Daniele Fallin
Journal:  Curr Psychiatry Rep       Date:  2020-11-20       Impact factor: 5.285

7.  An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease.

Authors:  Sufeng Zhang; Joerg Ermann; Marc D Succi; Allen Zhou; Matthew J Hamilton; Bonnie Cao; Joshua R Korzenik; Jonathan N Glickman; Praveen K Vemula; Laurie H Glimcher; Giovanni Traverso; Robert Langer; Jeffrey M Karp
Journal:  Sci Transl Med       Date:  2015-08-12       Impact factor: 17.956

8.  Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial.

Authors:  Axel Dignass; Robert Schnabel; Jacek Romatowski; Vladimir Pavlenko; Andrey Dorofeyev; Jelena Derova; Laimas Jonaitis; Karin Dilger; Tanju Nacak; Roland Greinwald
Journal:  United European Gastroenterol J       Date:  2017-03-30       Impact factor: 4.623

Review 9.  Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment.

Authors:  Cristina Calviño-Suárez; Rocío Ferreiro-Iglesias; Iria Bastón-Rey; Manuel Barreiro-de Acosta
Journal:  Int J Environ Res Public Health       Date:  2021-07-04       Impact factor: 3.390

10.  Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.

Authors:  Kavinderjit Nanda; Alan C Moss
Journal:  Clin Pharmacol       Date:  2012-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.